-
HIV sequence databases.
AIDS Rev. 2003 Jan-Mar;5(1):52-61
PMID: 12875108
-
HIV-1 prophylactic vaccine trials in Thailand.
Curr HIV Res. 2005 Jan;3(1):17-30
PMID: 15638720
-
Multigene DNA priming-boosting vaccines protect macaques from acute CD4+-T-cell depletion after simian-human immunodeficiency virus SHIV89.6P mucosal challenge.
J Virol. 2003 Nov;77(21):11563-77
PMID: 14557642
-
Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences.
J Virol. 2003 Dec;77(24):13376-88
PMID: 14645592
-
HIV vaccine development: lessons from the past and promise for the future.
Curr HIV Res. 2003 Jan;1(1):101-20
PMID: 15043215
-
Immunogenicity of constrained monoclonal antibody A32-human immunodeficiency virus (HIV) Env gp120 complexes compared to that of recombinant HIV type 1 gp120 envelope glycoproteins.
J Virol. 2004 May;78(10):5270-8
PMID: 15113908
-
Requirement of diverse T-helper responses elicited by HIV vaccines: induction of highly targeted humoral and CTL responses.
Expert Rev Vaccines. 2004 Aug;3(4 Suppl):S53-64
PMID: 15285705
-
Immunogen sequence: the fourth tier of AIDS vaccine design.
Expert Rev Vaccines. 2004 Aug;3(4 Suppl):S151-9
PMID: 15285713
-
Centralized immunogens as a vaccine strategy to overcome HIV-1 diversity.
Expert Rev Vaccines. 2004 Aug;3(4 Suppl):S161-8
PMID: 15285714
-
Cloning of HTLV-4 and its relation to simian and human immunodeficiency viruses.
Nature. 1987 Apr 9-15;326(6113):610-3
PMID: 3104797
-
N-glycosylation of HIV-gp120 may constrain recognition by T lymphocytes.
J Immunol. 1991 Nov 1;147(9):3128-32
PMID: 1717587
-
Neutralization of divergent HIV-1 isolates by conformation-dependent human antibodies to Gp120.
Science. 1991 Oct 4;254(5028):105-8
PMID: 1718036
-
Native but not denatured recombinant human immunodeficiency virus type 1 gp120 generates broad-spectrum neutralizing antibodies in baboons.
J Virol. 1992 Jan;66(1):172-82
PMID: 1727480
-
Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene.
J Virol. 1992 Apr;66(4):2232-9
PMID: 1548759
-
DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations.
Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):11478-82
PMID: 8265577
-
CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice.
Nucleic Acids Res. 1994 Nov 11;22(22):4673-80
PMID: 7984417
-
Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection.
N Engl J Med. 1995 Jan 26;332(4):201-8
PMID: 7808485
-
The genetic data environment an expandable GUI for multiple sequence analysis.
Comput Appl Biosci. 1994 Dec;10(6):671-5
PMID: 7704666
-
Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity.
J Virol. 1995 Nov;69(11):6705-11
PMID: 7474080
-
Maintaining the integrity of human immunodeficiency virus sequence databases.
J Virol. 1996 Aug;70(8):5720-30
PMID: 8764096
-
An improved plasmid DNA expression vector for direct injection into skeletal muscle.
Hum Gene Ther. 1996 Jun 20;7(10):1205-17
PMID: 8793545
-
Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection.
J Virol. 1999 Dec;73(12):10489-502
PMID: 10559367
-
Codon usage tabulated from international DNA sequence databases: status for the year 2000.
Nucleic Acids Res. 2000 Jan 1;28(1):292
PMID: 10592250
-
Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys.
Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4192-7
PMID: 10759543
-
Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120.
J Virol. 2000 Sep;74(18):8358-67
PMID: 10954535
-
Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140.
J Virol. 2001 Jan;75(2):645-53
PMID: 11134278
-
Localization of CD4+ T cell epitope hotspots to exposed strands of HIV envelope glycoprotein suggests structural influences on antigen processing.
Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4587-92
PMID: 11287644
-
The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region.
J Virol. 2001 Jun;75(12):5526-40
PMID: 11356960
-
Evolutionary and immunological implications of contemporary HIV-1 variation.
Br Med Bull. 2001;58:19-42
PMID: 11714622
-
Clinical trials of HIV vaccines.
Annu Rev Med. 2002;53:207-21
PMID: 11818471
-
Purification and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus.
J Virol. 2002 Mar;76(6):2835-47
PMID: 11861851
-
Role of N-linked glycans in a human immunodeficiency virus envelope glycoprotein: effects on protein function and the neutralizing antibody response.
J Virol. 2002 May;76(9):4199-211
PMID: 11932385
-
Past, present and future of HIV vaccine trials in developing countries.
Vaccine. 2002 May 6;20(15):1897-8
PMID: 11983240
-
HIV vaccine strategies.
Vaccine. 2002 May 6;20(15):1945-7
PMID: 11983251
-
Association of chemokine-mediated block to HIV entry with coreceptor internalization.
J Biol Chem. 2002 May 10;277(19):17291-9
PMID: 11782464
-
HIV type 1 variants transmitted to women in Kenya require the CCR5 coreceptor for entry, regardless of the genetic complexity of the infecting virus.
AIDS Res Hum Retroviruses. 2002 May 20;18(8):567-76
PMID: 12036486
-
Diversity considerations in HIV-1 vaccine selection.
Science. 2002 Jun 28;296(5577):2354-60
PMID: 12089434
-
HIV-1 diversity and vaccine development.
Science. 2002 Jun 28;296(5577):2335
PMID: 12090274
-
Crosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques.
Proc Natl Acad Sci U S A. 2002 Sep 3;99(18):11842-7
PMID: 12192089
-
Consensus and ancestral state HIV vaccines.
Science. 2003 Mar 7;299(5612):1515-8; author reply 1515-8
PMID: 12624248
-
Antibody neutralization and escape by HIV-1.
Nature. 2003 Mar 20;422(6929):307-12
PMID: 12646921
-
Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design.
J Virol. 2003 May;77(10):5889-901
PMID: 12719582
-
Predicting demographic group structures based on DNA sequence data.
Mol Biol Evol. 2003 Jul;20(7):1168-80
PMID: 12777527
-
Safety and immunogenicity of combinations of recombinant subtype E and B human immunodeficiency virus type 1 envelope glycoprotein 120 vaccines in healthy Thai adults.
J Infect Dis. 2003 Jul 15;188(2):219-27
PMID: 12854076
-
Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals.
J Virol. 1997 May;71(5):3734-41
PMID: 9094648
-
Human immunodeficiency virus type 1 coreceptors participate in postentry stages in the virus replication cycle and function in simian immunodeficiency virus infection.
J Virol. 1997 May;71(5):3932-9
PMID: 9094670
-
Seq-Gen: an application for the Monte Carlo simulation of DNA sequence evolution along phylogenetic trees.
Comput Appl Biosci. 1997 Jun;13(3):235-8
PMID: 9183526
-
Refocusing neutralizing antibody response by targeted dampening of an immunodominant epitope.
J Immunol. 1997 Jul 1;159(1):279-89
PMID: 9200464
-
Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit.
Vaccine. 1997 Jun;15(8):869-73
PMID: 9234536
-
Evolution of a simian immunodeficiency virus pathogen.
J Virol. 1998 Jan;72(1):405-14
PMID: 9420239
-
Immunogenicity of DNA vaccines expressing human immunodeficiency virus type 1 envelope glycoprotein with and without deletions in the V1/2 and V3 regions.
AIDS Res Hum Retroviruses. 1998 Jan 20;14(2):151-5
PMID: 9462925
-
A role for carbohydrates in immune evasion in AIDS.
Nat Med. 1998 Jun;4(6):679-84
PMID: 9623976
-
The antigenic structure of the HIV gp120 envelope glycoprotein.
Nature. 1998 Jun 18;393(6686):705-11
PMID: 9641684
-
Neutralization profiles of primary human immunodeficiency virus type 1 isolates in the context of coreceptor usage.
J Virol. 1998 Sep;72(9):6988-96
PMID: 9696790
-
Advancing AIDSVAX to phase 3. Safety, immunogenicity, and plans for phase 3.
AIDS Res Hum Retroviruses. 1998 Oct;14 Suppl 3:S325-31
PMID: 9814961
-
MODELTEST: testing the model of DNA substitution.
Bioinformatics. 1998;14(9):817-8
PMID: 9918953
-
Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin.
Glycobiology. 2004 Dec;14(12):1229-46
PMID: 15175256
-
Demographic factors that influence the neutralizing antibody response in recipients of recombinant HIV-1 gp120 vaccines.
J Infect Dis. 2004 Dec 1;190(11):1962-9
PMID: 15529261
-
Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies.
J Virol. 2004 Dec;78(23):13232-52
PMID: 15542675
-
Analysis of the neutralizing antibody response elicited in rabbits by repeated inoculation with trimeric HIV-1 envelope glycoproteins.
Virology. 2005 Jan 5;331(1):33-46
PMID: 15582651
-
Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein.
J Virol. 2005 Jan;79(2):1154-63
PMID: 15613343
-
Assorted mutations in the envelope gene of simian immunodeficiency virus lead to loss of neutralization resistance against antibodies representing a broad spectrum of specificities.
J Virol. 2003 Sep;77(18):9993-10003
PMID: 12941910